An Open, Non-controlled, Non-randomised, Parallel-group Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of AZD 8848 Administered Intranasally to Male and Female Butyrylcholinesterase Deficient Subjects and to Sex and Age Matched Controls
Latest Information Update: 06 Nov 2021
At a glance
- Drugs DSP 3025 (Primary)
- Indications Allergic asthma; Seasonal allergic rhinitis
- Focus Adverse reactions
- Sponsors AstraZeneca
- 19 Nov 2014 New trial record